RBC Capital Mkts slashes price target on Agile Therapeutics Inc. [AGRX] – find out why.

Related

Agile Therapeutics Inc. [NASDAQ: AGRX] stock went on an upward path that rose over 10.43% on Monday, amounting to a one-week price increase of more than 10.43%. The company report on May 17, 2022 that Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL. Details on the Company presentation are as follows:.

Over the last 12 months, AGRX stock dropped by -97.65%. The one-year Agile Therapeutics Inc. stock forecast points to a potential upside of 98.73. The average equity rating for AGRX stock is currently 2.50, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $6.07 million, with 3.12 million shares outstanding and 2.85 million shares in the current float. Compared to the average trading volume of 507.91K shares, AGRX stock reached a trading volume of 48141659 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Agile Therapeutics Inc. [AGRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGRX shares is $100.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGRX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Agile Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Janney raised their target price to Buy. The new note on the price target was released on April 12, 2019, representing the official price target for Agile Therapeutics Inc. stock. Previously, the target price had yet another raise to $3, while Maxim Group analysts kept a Buy rating on AGRX stock.

The Average True Range (ATR) for Agile Therapeutics Inc. is set at 0.15, with the Price to Sales ratio for AGRX stock in the period of the last 12 months amounting to 1.07. The Price to Book ratio for the last quarter was 2.12.

AGRX Stock Performance Analysis:

Agile Therapeutics Inc. [AGRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.43. With this latest performance, AGRX shares dropped by -5.93% in over the last four-week period, additionally sinking by -94.23% over the last 6 months – not to mention a drop of -97.65% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGRX stock in for the last two-week period is set at 37.68, with the RSI for the last a single of trading hit 49.53, and the three-weeks RSI is set at 32.24 for Agile Therapeutics Inc. [AGRX]. The present Moving Average for the last 50 days of trading for this stock 2.2473, while it was recorded at 1.1720 for the last single week of trading, and 16.9607 for the last 200 days.

Insight into Agile Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Agile Therapeutics Inc. [AGRX] shares currently have an operating margin of -1731.41 and a Gross Margin at -32.11. Agile Therapeutics Inc.’s Net Margin is presently recorded at -1826.24.

Return on Equity for this stock declined to -255.62, with Return on Assets sitting at -133.27.

Agile Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.60.

Agile Therapeutics Inc. [AGRX] Insider Position Details

There are presently around $25 million, or 24.90% of AGRX stock, in the hands of institutional investors. The top three institutional holders of AGRX stocks are: PERCEPTIVE ADVISORS LLC with ownership of 21,294,485, which is approximately 3900.001% of the company’s market cap and around 0.30% of the total institutional ownership; ARMISTICE CAPITAL, LLC, holding 113,678 shares of the stock with an approximate value of $0.13 million in AGRX stocks shares; and VANGUARD GROUP INC, currently with $0.11 million in AGRX stock with ownership of nearly -13.735% of the company’s market capitalization.

Positions in Agile Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 19 institutional holders increased their position in Agile Therapeutics Inc. [NASDAQ:AGRX] by around 20,900,598 shares. Additionally, 23 investors decreased positions by around 65,898 shares, while 12 investors held positions by with 813,910 shares. The mentioned changes placed institutional holdings at 21,780,406 shares, according to the latest SEC report filing. AGRX stock had 6 new institutional investments in for a total of 119,639 shares, while 12 institutional investors sold positions of 37,930 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]